Vanguard Group Inc. Has $23.41 Million Stock Position in AngioDynamics, Inc. $ANGO

Key Points

• Vanguard Group Inc. increased its ownership in AngioDynamics, Inc. by 8.7%, acquiring additional shares to own approximately 6.14% of the company, valued at around $23.4 million.
• AngioDynamics reported a revenue of $80.16 million in its latest earnings release, which exceeded analyst estimates and represented a 13% year-over-year growth.
• Several analysts have upgraded their ratings on AngioDynamics, with a consensus rating of "Buy" and a target price of $19.00, reflecting positive sentiment in the stock’s potential.

Vanguard Group Inc. raised its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 8.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,492,563 shares of the medical instruments supplier's stock after acquiring an additional 199,944 shares during the quarter. Vanguard Group Inc. owned approximately 6.14% of AngioDynamics worth $23,405,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ANGO. Phocas Financial Corp. acquired a new stake in shares of AngioDynamics in the 1st quarter valued at approximately $3,177,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of AngioDynamics in the first quarter valued at $139,000. GSA Capital Partners LLP bought a new position in shares of AngioDynamics in the first quarter valued at $642,000. Essex Investment Management Co. LLC bought a new position in shares of AngioDynamics in the first quarter valued at $1,683,000. Finally, Mackenzie Financial Corp grew its stake in shares of AngioDynamics by 20.5% in the first quarter. Mackenzie Financial Corp now owns 77,445 shares of the medical instruments supplier's stock valued at $727,000 after buying an additional 13,152 shares in the last quarter. 89.43% of the stock is owned by institutional investors.

AngioDynamics Price Performance

ANGO stock traded up $0.16 during midday trading on Wednesday, reaching $10.62. 540,872 shares of the company were exchanged, compared to its average volume of 343,511. The business has a 50-day moving average price of $9.24 and a two-hundred day moving average price of $9.56. AngioDynamics, Inc. has a one year low of $5.83 and a one year high of $13.50. The firm has a market capitalization of $431.49 million, a price-to-earnings ratio of -12.80 and a beta of 0.64.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The firm had revenue of $80.16 million during the quarter, compared to analysts' expectations of $74.26 million. During the same period in the previous year, the business posted ($0.06) earnings per share. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. As a group, analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANGO has been the subject of several analyst reports. Canaccord Genuity Group raised their target price on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. Wall Street Zen raised shares of AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Lake Street Capital initiated coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They issued a "buy" rating and a $24.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a research note on Wednesday, July 16th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $19.00.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.